[HTML][HTML] Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …
cells from exhausted status and revive immune response against cancer cells. Based on the …
[HTML][HTML] Recent advances in therapeutic strategies for triple-negative breast cancer
Y Li, H Zhang, Y Merkher, L Chen, N Liu… - Journal of hematology & …, 2022 - Springer
Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …
Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer
Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
negative breast cancer is defined by the presence of the estrogen receptor and/or the …
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …
[HTML][HTML] Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
[HTML][HTML] Immunotherapy in lung cancer: current landscape and future directions
H Mamdani, S Matosevic, AB Khalid, G Durm… - Frontiers in …, 2022 - frontiersin.org
Over the past decade, lung cancer treatment has undergone a major paradigm shift. A
greater understanding of lung cancer biology has led to the development of many effective …
greater understanding of lung cancer biology has led to the development of many effective …
[HTML][HTML] The future of cancer immunotherapy: microenvironment-targeting combinations
YR Murciano-Goroff, AB Warner, JD Wolchok - Cell research, 2020 - nature.com
Immunotherapy holds the potential to induce durable responses, but only a minority of
patients currently respond. The etiologies of primary and secondary resistance to …
patients currently respond. The etiologies of primary and secondary resistance to …
[HTML][HTML] Triple‑negative breast cancer therapy: Current and future perspectives
KA Won, C Spruck - International journal of …, 2020 - … .spandidos-publications.com
Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …
[HTML][HTML] Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …